In this context, Ahmed et al., recently reported, for the first time, the development of MRI-trackable dual-targeted IONPs to selectively and preferentially deliver the chemotherapeutic paclitaxel (PTX) to prostate cancer cells, taking advantage of the simultaneous overexpression of uPAR and the luteinizing hormone-releasing hormone receptor (LHRH-R) in this cancer type [243]. This evidence concerns the gene PLAUR and prostate cancer.